Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2006 3
2007 1
2008 3
2009 6
2010 5
2011 7
2012 14
2013 13
2014 8
2015 5
2016 5
2017 7
2018 5
2019 6
2020 10
2021 11
2022 9
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Zhu AX, et al. Among authors: toh hc. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. Nat Med. 2022. PMID: 35739268
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Organoids as an Enabler of Precision Immuno-Oncology.
Zhao J, Fong A, Seow SV, Toh HC. Zhao J, et al. Among authors: toh hc. Cells. 2023 Apr 14;12(8):1165. doi: 10.3390/cells12081165. Cells. 2023. PMID: 37190074 Free PMC article. Review.
Immunotherapy for nasopharyngeal cancer-a review.
Jain A, Chia WK, Toh HC. Jain A, et al. Among authors: toh hc. Chin Clin Oncol. 2016 Apr;5(2):22. doi: 10.21037/cco.2016.03.08. Chin Clin Oncol. 2016. PMID: 27121882 Free article. Review.
Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC.
Suthen S, Lim CJ, Nguyen PHD, Dutertre CA, Lai HLH, Wasser M, Chua C, Lim TKH, Leow WQ, Loh TJ, Wan WK, Pang YH, Soon G, Cheow PC, Kam JH, Iyer S, Kow A, Tam WL, Shuen TWH, Toh HC, Dan YY, Bonney GK, Chan CY, Chung A, Goh BKP, Zhai W, Ginhoux F, Chow PKH, Albani S, Chew V. Suthen S, et al. Among authors: toh hc. Hepatology. 2022 Nov;76(5):1329-1344. doi: 10.1002/hep.32419. Epub 2022 Mar 17. Hepatology. 2022. PMID: 35184329
Cancer immunotherapy-the end of the beginning.
Toh HC. Toh HC. Chin Clin Oncol. 2018 Apr;7(2):12. doi: 10.21037/cco.2018.04.03. Chin Clin Oncol. 2018. PMID: 29764157 Free article. No abstract available.
A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma.
Tan TJ, Ang WXG, Wang WW, Chong HS, Tan SH, Cheong R, Chia JW, Syn NL, Shuen WH, Ba R, Kaliaperumal N, Au B, Hopkins R, Li X, Tan AC, Seet AOL, Connolly JE, Arkachaisri T, Chew V, Lajam ABM, Guo D, Chew MZW, Wasser M, Kumar P, Albani S, Toh HC. Tan TJ, et al. Among authors: toh hc. Nat Commun. 2022 Oct 28;13(1):6453. doi: 10.1038/s41467-022-33834-4. Nat Commun. 2022. PMID: 36307410 Free PMC article. Clinical Trial.
121 results